BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) announced this week that the U.S. Food and Drug Administration ...

Larimar Therapeutics announces FDA lift of partial clinical hold on nomlabofusp (CTI-1601) for Friedreich's Ataxia. Data from Phase 2 study shows well-tolerated treatment with significant frataxin ...

Larimar Therapeutics’ Friedreich’s ataxia program is free at last, with the FDA fully lifting a clinical hold that had ...

Shares of Larimar Therapeutics, Inc.. (NASDAQ:LRMR) rose sharply in today's pre-market trading after the company announced ...

Larimar will continue the open label extension study in Friedreich’s ataxia with results expected in Q4 this year.

Larimar (LRMR) said the FDA has removed a partial clinical hold on its nomlabofusp clinical program following a review of ...

Leerink Partners raised the price target for the Larimar Therapeutics Inc (NASDAQ:LRMR) stock to “an Outperform”. The rating was released on April 03, 2024, according to finviz. The research report ...

(RTTNews) - Larimar Therapeutics, Inc. (LRMR) Tuesday announced that FDA has removed the partial clinical hold placed on its nomlabofusp or CTI-1601, a clinical program targeting treatment of patients ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

By Stephen Nakrosis Shares of Larimar Therapeutics were trading higher in after-hours action Monday, following news the U.S. Food and Drug Administration ...

Given this risk, we thought we'd take a look at whether Larimar Therapeutics (NASDAQ:LRMR) shareholders should be worried ...

BALA CYNWYD, Pa. — BALA CYNWYD, Pa. — Larimar Therapeutics, Inc. (LRMR) on Thursday reported a loss of $14.7 million in its first quarter. On a per-share basis, the Bala Cynwyd, Pennsylvania-based ...